Project Grant R01CA316828
Award Date 6/15/26
Completion Date 5/31/31
Dollars Obligated $408K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the University of Nebraska Medical Center a Project Grant of $394,687 under the Cancer Treatment Research program (CFDA 93.395) for the period of June 10, 2026 through May 31, 2028. The research focuses on identifying molecular drivers of pancreatic ductal adenocarcinoma (PDAC) health disparities between racial populations, with the objective of developing improved treatment strategies. Specifically, the project examines...
- Federal Grant Award Summary The National Cancer Institute awarded a $411,206 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This award supports the development of small molecule inhibitors targeting the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma (PDAC) therapy. The research addresses a critical clinical need, as PDAC accounts for approximately 90%...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a Project Grant totaling $408,829 under the Cancer Treatment Research program (CFDA 93.395) to investigate lipogenesis-mediated resistance to cytotoxic therapy in pancreatic ductal adenocarcinoma (PDAC). The award, effective May 25, 2026 through April 30, 2028, supports fundamental research aimed at characterizing how tumor cells use de novo lipid production to escape cell death mechanisms and evade...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $501,803 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) effective June 1, 2026, through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied laboratory research focused on decoding the stromal microenvironment of pancreatic ductal adenocarcinoma (PDAC), specifically examining the role of antigen-presenting...
- Federal Grant Award Summary Purdue University received a $457,503 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 28, 2025, with completion targeted for July 31, 2030. The research project focuses on elucidating the posttranslational regulation of macropinocytosis in pancreatic ductal adenocarcinoma (PDAC), specifically investigating the role of protein phosphatase 2A (PP2A) subunit B56A in regulating nutrient-scavenging...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Project Grant Award Summary Florida State University's Sponsored Research Administration Division received a $567,264 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded June 10, 2026, with a completion date of May 31, 2031. The award supports fundamental research investigating the role of cellular physical interactions in pancreatic cancer progression. Pancreatic ductal adenocarcinoma (PDAC) represents a critical...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Oklahoma Health Sciences Center a $424,480 Project Grant on September 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The four-year award, extending through August 31, 2029, supports research activities aimed at promoting Lead Academic Participating Sites (LAPS) studies accrual and lung cancer screening in Oklahoma. The grant funds the principal investigator's continued engagement with the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $145,000.00 in funding to the University of Oklahoma Health Sciences Center to investigate the role of the JMJD4 enzyme in pancreatic cancer. The research aims to determine how JMJD4 affects the growth and invasiveness of pancreatic tumor cells, as well as its potential mechanisms of action through modulating transcription factors NRF2 and HIF-2A. This work is expected to advance...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2029. This NCI Research Specialist (Clinician Scientist) Award supports an Associate Professor of Urologic Oncology who serves as the Stevenson Chair at the Stephenson Cancer Center to advance cancer screening and clinical trial enrollment...